IRIS
BATTISTA, TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.063
NA - Nord America 2.230
EU - Europa 1.897
SA - Sud America 380
AF - Africa 83
Continente sconosciuto - Info sul continente non disponibili 68
OC - Oceania 4
Totale 7.725
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.118
SG - Singapore 1.304
RU - Federazione Russa 875
CN - Cina 743
DE - Germania 546
VN - Vietnam 408
BR - Brasile 314
HK - Hong Kong 173
IT - Italia 159
IN - India 126
KR - Corea 95
FI - Finlandia 81
FR - Francia 68
CA - Canada 55
JP - Giappone 48
BD - Bangladesh 45
GB - Regno Unito 44
AR - Argentina 30
CI - Costa d'Avorio 26
ZA - Sudafrica 24
MX - Messico 23
NL - Olanda 18
IQ - Iraq 17
PK - Pakistan 17
UA - Ucraina 16
PL - Polonia 15
ES - Italia 14
EC - Ecuador 13
ID - Indonesia 13
PH - Filippine 11
AT - Austria 10
CR - Costa Rica 8
KE - Kenya 8
MA - Marocco 8
TH - Thailandia 8
IE - Irlanda 7
SA - Arabia Saudita 7
SE - Svezia 7
TR - Turchia 7
EG - Egitto 6
JO - Giordania 6
LT - Lituania 6
PY - Paraguay 6
TW - Taiwan 6
CO - Colombia 5
IL - Israele 5
JM - Giamaica 5
RS - Serbia 5
CL - Cile 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
VE - Venezuela 4
AZ - Azerbaigian 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
MY - Malesia 3
OM - Oman 3
PR - Porto Rico 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BE - Belgio 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
KH - Cambogia 2
LB - Libano 2
NI - Nicaragua 2
PE - Perù 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
AF - Afghanistan, Repubblica islamica di 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
BZ - Belize 1
CG - Congo 1
EE - Estonia 1
GA - Gabon 1
GN - Guinea 1
GR - Grecia 1
HT - Haiti 1
HU - Ungheria 1
KG - Kirghizistan 1
KW - Kuwait 1
LC - Santa Lucia 1
LV - Lettonia 1
MD - Moldavia 1
MQ - Martinica 1
MR - Mauritania 1
NC - Nuova Caledonia 1
NO - Norvegia 1
PA - Panama 1
PG - Papua Nuova Guinea 1
Totale 7.653
Salva come PNG Salva come JPEG
Città #
Singapore 690
San Jose 414
Hefei 386
Moscow 228
Ashburn 224
Santa Clara 176
Hong Kong 166
Ho Chi Minh City 127
Beijing 124
Munich 113
Krefeld 111
Hanoi 93
Council Bluffs 83
Seoul 83
Kochi 82
Chandler 74
Los Angeles 61
Lauterbourg 55
Helsinki 52
Tokyo 44
New York 43
The Dalles 43
Bad Bellingen 42
São Paulo 36
Dallas 30
Milan 29
Redondo Beach 28
Chicago 26
Buffalo 23
Da Nang 22
Phoenix 21
Boardman 19
Boston 17
Houston 17
Rome 17
Naples 16
Haiphong 15
Lappeenranta 14
Brooklyn 13
Chennai 13
Frankfurt am Main 13
Montreal 13
Rio de Janeiro 13
Warsaw 13
Biên Hòa 12
Orem 12
Seattle 12
Toronto 12
Atlanta 11
London 11
Mexico City 11
Pune 10
Falkenstein 9
San José 8
Denver 7
Lahore 7
Porto Alegre 7
Rochdale 7
San Francisco 7
Xi'an 7
Amman 6
Belo Horizonte 6
Campinas 6
Dublin 6
Jyväskylä 6
Manchester 6
Nairobi 6
Poplar 6
Ribeirão Preto 6
Stockholm 6
Turku 6
Amsterdam 5
Bắc Giang 5
Calgary 5
Campo Grande 5
Charlotte 5
Curitiba 5
Erbil 5
Figino 5
Guangzhou 5
Johannesburg 5
Karlsruhe 5
Kingston 5
Nuremberg 5
Quito 5
Washington 5
Can Tho 4
Düsseldorf 4
Florence 4
Fortaleza 4
Guayaquil 4
Memphis 4
Paris 4
Phủ Lý 4
Salvador 4
Santo André 4
Turin 4
Zhengzhou 4
Ankara 3
Athens 3
Totale 4.267
Salva come PNG Salva come JPEG
Nome #
Effect of Dupilumab on Sexual Desire in Adult Patients with Moderate to Severe Atopic Dermatitis 476
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study 407
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study 171
Alopecia Areata after COVID-19 Vaccines 167
Management of Psoriasis Patients with Serious Infectious Diseases 160
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis 160
Real-world practice indirect comparison between guselkumab, risankizumab and tildrakizumab: results from an Italian 28-week retrospective study 146
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience 142
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 141
Hidradenitis Suppurativa Cancer Risk: A Review of the Literature 139
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature 137
Comment on ‘Anogenital dermatology: challenges in the digital era’ 137
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 135
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature 134
The impact of COVID ‐19 infection on psoriatic patients treated with biologics: an Italian experience 132
An uncommon case of lichen spinulosus induced by dupilumab in a patient treated for bronchial asthma 131
Treatment of hereditary hypotrichosis simplex of the scalp with oral minoxidil and growth factors 129
Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real‐life study 126
Risk Factors for Psoriasis Flares: A Narrative Review 125
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials 125
COVID-19 and cutaneous manifestations: A review of the published literature 125
Acrodermatitis continua of Hallopeau successfully treated with ixekizumab: A case report 125
Leg paralysis after photodynamic therapy for Lymphomatoid Papulosis: a case report 125
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis 124
Generalized versus localized vitiligo after ixekizumab: May previous treatment affect the clinical presentation? 122
Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19 118
Immune response to Covid‐19 mRNA vaccination in psoriasis patients undergoing treatment with biologics 117
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 115
Epidermolysis bullosa: new insights for the future 114
Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a psoriasis patient. Comment on "Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab" 113
Comment on ‘Pityriasis rubra pilaris-like eruption following mRNA COVID-19 vaccine’ 111
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? 111
Reply to “Nail psoriasis: a rare mRNA COVID ‐19 vaccine reaction” by Lamberti A et al 111
A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab 110
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review 107
Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study 105
Comment on 'Morphoea following COVID-19 vaccination' 104
Dupilumab for the treatment of adult atopic dermatitis in special populations 103
Comment on: "Associations between hidradenitis suppurativa and dermatological conditions in adults: A national cross-sectional study by Brown et al." 103
Pemphigus Vulgaris and COVID-19 vaccination: Management and Treatment 103
Guselkumab-induced vitiligo in a patient with psoriatic arthritis 102
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature 101
Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review 99
Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: 'Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa' 99
Atypical case of cutaneous Rosai-Dorfman disease 96
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study 96
Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes—A Review of the Literature 95
COVID-19 vaccination and inflammatory skin diseases 95
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report 90
Reply to ‘Effectiveness, safety and drug survival of oral roflumilast for hidradenitis suppurativa’ by Holgersen et al 90
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data 87
Viral Reactivation Following COVID-19 Vaccination: a review of the current literature 87
Reply to “Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa” 74
Bullous pemphigoid and COVID ‐19 vaccination: management and treatment Reply to ‘Bullous pemphigoid in a young male after COVID ‐19 mRNA vaccine: a report and brief literature review’ by Pauluzzi et al 71
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report 69
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study 69
Reply to “Dalbavancin for the treatment of severe hidradenitis suppurativa” 68
Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging Association 66
Comment on ‘Eosinophilic pustular folliculitis developing at the site of COVID-19 vaccination’ 65
Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments 65
Allergic contact dermatitis to petrolatum: An unknown for patch testing 64
Advancing Dermatology: Embracing the Power of Artificial Intelligence 64
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era? 62
Comment on ‘Onset of epidermolysis bullosa acquisita under therapy with ustekinumab for the treatment of Crohn disease’ 56
The impact of tildrakizumab on quality of life in patients suffering from moderate-to-severe psoriasis: a 36-week prospective, monocentric, real-life, observational study 55
Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient 54
Totale 7.725
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.759
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.759
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20229 0 0 0 0 0 0 0 1 0 1 2 5
2022/2023284 4 16 3 15 35 29 13 40 37 18 33 41
2023/2024657 11 41 49 22 13 28 10 50 316 16 60 41
2024/20252.199 77 92 15 12 85 171 221 176 150 263 789 148
2025/20263.895 414 645 424 426 565 158 333 223 355 181 88 83
2026/2027681 266 134 158 123 0 0 0 0 0 0 0 0
Totale 7.725